Taisho Pharmaceutical Holdings Co., Ltd.
TAISF · OTC
3/31/2023 | 3/31/2022 | 3/31/2021 | 3/31/2020 | |
|---|---|---|---|---|
| Revenue | $301,381 | $268,203 | $282,037 | $288,720 |
| % Growth | 12.4% | -4.9% | -2.3% | – |
| Cost of Goods Sold | $123,531 | $104,371 | $106,050 | $108,337 |
| Gross Profit | $177,850 | $163,832 | $175,987 | $180,383 |
| % Margin | 59% | 61.1% | 62.4% | 62.5% |
| R&D Expenses | $20,727 | $19,366 | $20,251 | $22,876 |
| G&A Expenses | $84,648 | $82,318 | $78,376 | $74,492 |
| SG&A Expenses | $134,104 | $133,722 | $135,770 | $136,047 |
| Sales & Mktg Exp. | $49,456 | $51,404 | $57,394 | $61,555 |
| Other Operating Expenses | $322 | -$136 | $335 | $170 |
| Operating Expenses | $154,831 | $153,088 | $156,021 | $158,923 |
| Operating Income | $23,018 | $10,743 | $19,965 | $21,460 |
| % Margin | 7.6% | 4% | 7.1% | 7.4% |
| Other Income/Exp. Net | $4,175 | $8,827 | $1,133 | $8,637 |
| Pre-Tax Income | $27,193 | $19,570 | $21,098 | $30,311 |
| Tax Expense | $8,196 | $6,448 | $7,782 | $8,423 |
| Net Income | $18,997 | $13,122 | $13,316 | $20,172 |
| % Margin | 6.3% | 4.9% | 4.7% | 7% |
| EPS | 231.72 | 161.12 | 166.83 | 252.73 |
| % Growth | 43.8% | -3.4% | -34% | – |
| EPS Diluted | 231.42 | 160.93 | 166.63 | 252.44 |
| Weighted Avg Shares Out | 82 | 81 | 80 | 80 |
| Weighted Avg Shares Out Dil | 82 | 82 | 80 | 80 |
| Supplemental Information | – | – | – | – |
| Interest Income | $1,592 | $1,338 | $1,690 | $3,769 |
| Interest Expense | $169 | $170 | $156 | $118 |
| Depreciation & Amortization | $24,648 | $23,074 | $22,041 | $16,695 |
| EBITDA | $54,315 | $44,642 | $45,173 | $41,824 |
| % Margin | 18% | 16.6% | 16% | 14.5% |